Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist ) to Children Aged 2--4 Years and Other FluMist Changes for the 2007--08 Influenza Season. MMWR 2007. 56 (46): 1217-1219.

Details

• Description:
  On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist , a live, attenuated influenza vaccine (LAIV), to children aged 2--4 years (i.e., 24--49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5--49 years (1). Expanding the age indications to include healthy children aged 2--4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications (2). In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing (1,2).
• Document Type:
  Journal Article
• Collection(s):
  Guidelines and Recommendations
• Main Document Checksum:
  urn:sha-512:f40f7b52ff37b49ea932486c0fd1dbf02c277d0fdb5b446ecaa2f1327698b54adbc5b578d097811ffe2b7e8cb6b351a55df7a82c34de9e187246b15a179e2932
• Download URL:
  https://stacks.cdc.gov/view/cdc/7513/cdc_7513_DS1.pdf
• File Type:
  [PDF - 442.78 KB ]